Join the Future of Robotic Biomanufacturing! Multiply Labs is a robotics company on a mission to solve a significant bottleneck in modern medicine: the manufacturing of life-saving advanced biologics, from gene and cell therapies to antibodies and more. Today, these therapies are produced through manual, labor-intensive processes. Costs are extremely high—often $500K–$2M per patient—limiting access to only a small fraction of those who need them. As product complexity increases and the cost of failure and scientific labor rises, the industry is shifting toward automation. Robotics and AI are making automated biologics manufacturing feasible, reliable, and economically scalable. We believe the future of biomanufacturing is robotic—closed, automated, and scalable—ensuring critical therapeutics are accessible to every patient who needs them. Why This Matters We don’t just build robots; we build the infrastructure for the next generation of biologics manufacturing. Our technology allows biopharma companies to scale production without redesigning their science, drastically lowering regulatory hurdles and bringing costs down to a level where these treatments can actually reach patients. The Stack & The Scale The Mission: Build the world’s best robots to make life-saving therapies accessible to all. The Technology: Advanced robotic orchestration, high-precision automation, cloud-integrated hardware-software systems, dextrous manipulation, and imitation learning. The Location: Headquartered in San Francisco, CA. The Backing: Supported by premier investors, including Casdin Capital, Lux Capital, and Y Combinator.